webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

N-(2-(3-Ethoxyphenoxy)ethyl)-4-Formylbenzamide

  CAS No.: 1226006-55-8   Cat No.: BADC-00543 4.5  

N-(2-(3-Ethoxyphenoxy)ethyl)-4-Formylbenzamide is an aldehyde-functionalized ADC linker enabling selective bioorthogonal conjugation for site-specific antibody-drug conjugate synthesis and improved targeted payload delivery.

N-(2-(3-Ethoxyphenoxy)ethyl)-4-Formylbenzamide

Structure of 1226006-55-8

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Linker
Molecular Formula
C18H19NO4
Molecular Weight
313.35
Shipping
Room temperature

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
IUPAC Name
N-[2-(3-ethoxyphenoxy)ethyl]-4-formylbenzamide
Canonical SMILES
CCOC1=CC(=CC=C1)OCCNC(=O)C2=CC=C(C=C2)C=O
InChI
InChI=1S/C18H19NO4/c1-2-22-16-4-3-5-17(12-16)23-11-10-19-18(21)15-8-6-14(13-20)7-9-15/h3-9,12-13H,2,10-11H2,1H3,(H,19,21)
InChIKey
YMULMQCAEQLXBL-UHFFFAOYSA-N
Shipping
Room temperature

N-(2-(3-Ethoxyphenoxy)ethyl)-4-Formylbenzamide is gaining notable attention within the pharmaceutical research community due to its unique molecular structure and significant potential for diverse therapeutic applications. The incorporation of ethoxyphenoxy and formylbenzamide groups into the compound’s framework allows for precise molecular interactions, making it an attractive candidate for drug development. These structural features not only confer potential biological activity but also provide the versatility needed to address various medical challenges, highlighting its role in advancing current treatment methodologies. Researchers are focused on understanding its full scope and potential across numerous disease pathways.

In the field of oncology, N-(2-(3-Ethoxyphenoxy)ethyl)-4-Formylbenzamide is being extensively studied for its potential as an anti-cancer agent. The compound is believed to interfere with key signaling pathways that regulate cell proliferation and apoptosis, thereby inhibiting tumor growth and progression. Its specificity in targeting cancer cells while sparing normal tissue presents a promising approach to cancer treatment, aiming to reduce the severe side effects associated with conventional therapies. Ongoing research aims to validate its effectiveness across different cancer types and establish it as a viable option in targeted cancer therapy.

Beyond its applications in oncology, this compound is noted for its potential anti-inflammatory properties. Chronic inflammatory diseases, such as rheumatoid arthritis and ulcerative colitis, could greatly benefit from treatments that effectively manage inflammation and provide sustained relief. N-(2-(3-Ethoxyphenoxy)ethyl)-4-Formylbenzamide is being investigated for its ability to modulate immune responses and decrease the production of pro-inflammatory cytokines. If successful, these studies could result in new therapies that not only alleviate symptoms but also impede disease progression, improving the quality of life for patients affected by chronic inflammatory disorders.

Additionally, N-(2-(3-Ethoxyphenoxy)ethyl)-4-Formylbenzamide shows exciting potential in neuroprotective applications. Neurodegenerative diseases, including Alzheimer’s and Parkinson’s disease, represent ongoing challenges in medicine due to their complex, progressive nature. This compound may provide neuroprotective effects by stabilizing neuronal cells and potentially slowing the progression of these disorders. By focusing on mechanisms that protect and maintain neuronal integrity, researchers hope to develop novel treatments that not only manage symptoms but also alter the disease course. These investigations underscore the compound’s versatility and potential to pioneer advances in therapeutic strategies for complex neurodegenerative conditions.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Linker Development Enzyme Cleavable Linker Cathepsin B Cleavable Linker/Peptide Linker Phosphatase Cleavable Linker β-Glucuronide Linker β-Galactosidase Cleavable Linker Sulfatase Cleavable Linker Chemically Cleavable Linker Non-Cleavable Linker Services Acid Cleavable Linker/Hydrazone Linker

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Linkers - A Crucial Factor in Antibody–Drug Conjugates In-Depth Review of ADC Linkers: Types, Mechanisms, and Research Progress New Structural Insights Solve Instability Issues of Maleimide Linkers in ADCs PEG Linkers in Antibody-Drug Conjugates Peptide Linkers in Antibody-Drug Conjugates Disulfide Linkers in Antibody-Drug Conjugates Biotinylation Reagents in Antibody-Drug Conjugates Maleimide Linkers in Antibody-Drug Conjugates Current ADC Linker Chemistry SPDB Linkers in Antibody-Drug Conjugates

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: N-Boc-diethanolamine | Gly-Gly-Gly-PEG4-azide | Gly-Gly-Gly-PEG3-TCO | Gly-Gly-Gly-PEG4-methyltetrazine | DM4-SPDP | Ald-PEG4-NHS ester | Azide-PEG4-VC-PAB-Doxorubicin | NHPI-PEG2-C2-NHS ester | DBCO-PEG4-Val-Cit-PAB-MMAF | Fmoc-N-amido-PEG2-acetic acid | N-(2-(3-Ethoxyphenoxy)ethyl)-4-Formylbenzamide
Send Inquiry
Verification code
Inquiry Basket